Compass Pathways stock rating reiterated at Buy by H.C. Wainwright

Compass Pathways received rolling FDA NDA submission and review for COMP360 in treatment-resistant depression, with a Commissioner’s National Priority Voucher that could compress final review to 1-2 months after NDA completion. H.C. Wainwright reiterated a Buy rating and $70 target, while other firms also remain positive; Q1 2026 EPS of -$0.30 beat the -$0.43 consensus and the company ended with $466 million in cash, supporting runway into 2028. The stock is up 161% over the past year and trades near its 52-week high of $11.28.

Analysis

CMPS is transitioning from a “hope story” to a process-control story, and that changes the trade. Once the regulatory clock shortens, the market usually stops pricing clinical binary risk and starts pricing execution risk: launch readiness, payer access, REMS friction, and scheduling capacity. That tends to compress the variance of outcomes but also raises the penalty for any operational stumble, so upside can persist while downside becomes sharper on missed milestones.

The second-order winner set is less obvious than just CMPS: specialty distributors, infusion-site operators, and adjacent psychedelic/psychiatric ecosystem names benefit if this becomes the first scalable commercial template in the category. The bigger competitive effect is on peers with similar late-stage assets—this validates regulatory pathways and could pull forward capital into the space, but it also forces investors to differentiate “real launchable assets” from concept-stage science. If CMPS clears the NDA cleanly, the multiple re-rate can spill over to the group even before revenue exists.

The main contrarian risk is that the market may be over-anchoring on approval and underestimating adoption friction. In a treatment-resistant depression setting, payers can be the true gatekeepers; if reimbursement is slow or site enrollment lags, the stock can retrace well before any headline FDA event. A second risk is timing mismatch: the next meaningful catalyst is months away, so the trade can decouple from fundamentals and become purely sentiment-driven in the interim, especially after a large run-up.

Key Decisions for Investors

• Stay long CMPS into the next regulatory module submissions, but use a staged entry and trim into strength; the setup favors a 3-6 month hold with asymmetric upside if approval odds continue rising, but the name is vulnerable to a 15-20% air pocket on any process delay.
• Buy CMPS call spreads 6-9 months out instead of common stock to express the approval/launch thesis; this captures upside through the next catalysts while defining risk if payer or REMS execution disappoints.
• Pair trade: long CMPS / short a basket of speculative CNS biotech names with weaker balance sheets and no near-term regulatory catalyst; the relative trade benefits if capital rotates toward de-risked commercial stories.
• If CMPS approaches the upper end of its recent range ahead of a catalyst, hedge with short-dated puts or reduce delta; the stock is likely to trade headline-to-headline until final NDA completion, making timing more important than conviction.